Skip to main content

Table 2 Univariate and multivariate analysis of prognostic factors for OS in patients with DLBCL

From: Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis

Parameters

Univariate analysis

Multivariate analysis

HR (95% CI)

P

HR (95% CI)

P

Age (>60 vs ≤60)

1.567 (0.850–2.891)

0.150

  

Sex (male vs female)

1.008 (0.550–1.848)

0.980

  

B symptoms (present vs absent)

2.302 (1.255–4.221)

0.007

  

LDH (>ULN vs normal)

4.022 (2.026–7.984)

<0.001

  

ECOG score (2-4 vs 0-1)

2.785 (1.518–5.108)

0.001

  

Ann Arbor Stage (III-IV vs I-II)

1.919 (0.967–3.810)

0.062

  

Extranodal disease (>1 vs ≤1)

2.089 (1.144–3.815)

0.017

  

IPI

 

<0.001

 

<0.001

 Low risk (0-1)

reference

 

reference

 

 Low-intermediate risk (2)

1.146 (0.408–3.219)

0.797

1.144 (0.407–3.215)

0.798

 High-intermediate risk (3)

4.044 (1.763–9.276)

0.001

3.516 (1.519–8.139)

0.003

 High risk (4-5)

5.441 (2.324–12.739)

<0.001

4.722 (1.999–11.154)

<0.001

Subtype (GCB vs non-GCB)

1.254 (0.795–1.979)

0.331

  

FFAs (high vs normal)

2.698 (1.385–5.258)

0.004

2.075 (1.051–4.096)

0.035